Background
Methods
Search strategy
Inclusion and exclusion criteria
Data extraction and definitions of outcome
Quality assessment
Statistical analysis
Results
Search results
Reference | Mothers’ age (years) | E 1)
| Immune prophylaxis | Sample size | Newborn | 7-12 month infant | >12 month child | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Mother (schedule/pregnancy month) | Child (schedule/infant month) | HBsAg+ | HBsAb+ | HBsAg+ | HBsAb+ | HBsAg+ | HBsAb+ | ||||
Ji 2003 [30] | 21-31 | 1 | T: HBIG 200 IU (7,8,9) | NR | T:29 | T:3 | T:10 | NR | NR | NR | NR |
C: none | C:31 | C:5 | C:3 | ||||||||
Xu 2006 [31] | NR | 1 | T: HBIG 200 IU (7,8,9) | NR | T:30 | T:7 | NR | NR | NR | NR | NR |
Repeated [32] | C: none | C:30 | C:20 | ||||||||
Yuan 2006 [22] | 20-33 | 1 | T: HBIG 400 IU (7,8,9) | T : HBIG 200 IU(0) + RV 5 ug(0,1,6) | T:118 | T:27 | T:0 | T:13 | T:101 | NR | NR |
C: Diluent | C: HBIG 200 IU(0) + RV 5 ug(0,1,6) | C:113 | C:32 | C:0 | C:17 | C:112 | |||||
Chen 2007 [33] | NR | 1 | T1: HBIG 200 IU (7,8,9) | T1: HBIG 200 IU(0,0.5) + RV 5 ug(0,1,6) | T1:45 | T1: 1 | T1: 14 | T1: 1 | T1:33 | NR | NR |
T2: None | T2: HBIG 200 IU(0,0.5) + RV 5 ug(0,1,6) | T2:44 | T2: No | T2: No | T2: 3 | T2: 35 | |||||
C:None | C: RV 5ug(0,1,6) | C:49 | C:13 | C: 4 | C: 13 | C: 32 | |||||
Sun 2007 [34] | NR | 1 | T1: HBIG 200 IU (7,8,9) | T1: HBIG 200 IU(0,0.5) + V 5 ug(0,1,6) | T1:77 | T1: 2 | NR | T1:1 | T1: 73 | T1:0 | T1: 54 |
T2:None | T2: HBIG 200 IU(0,0.5) + V 5 ug(0,1,6) | T2:76 | T2: 10 | T2: 4 | T2: 70 | T2:1 | T2: 50 | ||||
C: None | C : V 5ug(0,1,6) | C:70 | C: 9 | C: 8 | C: 58 | C: 4 | C: 30 | ||||
Wang 2007 [35] | NR | 1 | T: HBIG 200 IU (4–9) | T: HBIG 200 IU(0,0.5) + V 10 ug(1,2,7) | T:32 | T: 2 | NR | T: 2 | NR | NR | NR |
C: none | C: HBIG 200 IU(0,0.5) + V 10 ug(1,2,7) | C:31 | C: 11 | C: 12 | |||||||
Yan 2009 [36] | 22-35 | 1 | T: HBIG 400 IU (7,8,9) | T: HBIG 200 IU(0,0.5) + RV 10 ug(0,1,6) | T:106 | T:10 | T:37 | T: 9 | T: 82 | T:8 | T: 93 |
C: none | C: RV 10ug(0,1,6) | C:98 | C:23 | C: 9 | C: 21 | C: 46 | C:20 | C: 69 | |||
Cui 2011 [37] | NR | 1 | T: HBIG 200 IU, 3 time | T: HBIG 100 IU, 2time + RV 5 ug, 0, 1,6 | T:106 | NR | NR | NR | NR | T:5 | T:96 |
C: none | C: RV 5 ug, 0, 1,6 | C:82 | C:16 | C:60 | |||||||
Zhu 1997 [38] | NR | 1 | T: HBIG 200 IU (7,8,9) | NR | T:37 | T: 6 | NR | NR | NR | NR | NR |
C:32 | C: 12 | ||||||||||
Repeated [39] | 2 | C: none | T:68 | T: 0 | NR | NR | NR | NR | NR | ||
C:70 | C: 3 | ||||||||||
Jia 2001 [40] | NR | 1 | T: HBIG 200 IU (7,8,9) | NR | T:15 | T: 1 | NR | NR | NR | NR | NR |
C:16 | C: 7 | ||||||||||
2 | C: none | T:25 | T: 0 | NR | NR | NR | NR | NR | |||
C:30 | C: 3 | ||||||||||
Chi 2002 [41] | NR | 1 | T: HBIG 200 IU (7,8,9) | NR | T:27 | T:4 | NR | NR | NR | NR | NR |
C:29 | C:10 | ||||||||||
2 | C: none | T:42 | T: 0 | NR | NR | NR | NR | NR | |||
C:43 | C:2 | ||||||||||
Chen2003 [42] | NR | 1 | T: HBIG 200 IU (7,8,9) | NR | T:18 | T:2 | NR | NR | NR | NR | NR |
C:15 | C:6 | ||||||||||
2 | C: none | T:26 | T: 1 | NR | NR | NR | NR | NR | |||
C:20 | C: 2 | ||||||||||
Han 2003 [43] | NR | 1 | T: HBIG 200 IU (7,8,9) | T: HBIG 200 IU(0,0.5) + V 5 ug(1,2,7) | T:83 | T:21 | NR | T: 5 | NR | NR | NR |
C:52 | C:23 | C: 7 | |||||||||
Repeated [44] | 2 | C: None | C : HBIG 200 IU(0,0.5) + V 5 ug(1,2,7) | T:43 | T: 3 | NR | T: 0 | NR | NR | NR | |
C:38 | C: 9 | C: 5 | |||||||||
Xing 2003 [45] | 22-38 | 1 | T: HBIG 200 IU (7,8,9) | NR | T:16 | T: 2 | NR | NR | NR | NR | NR |
C:15 | C: 6 | ||||||||||
Repeated [46] | 2 | C: None | T:30 | T: 0 | NR | NR | NR | NR | NR | ||
C:25 | C: 3 | ||||||||||
Zhu 2003 [47] | NR | 1 | T: HBIG 200-400 IU (7,8,9) | T: HBIG 100 IU(0,0.5) + RV 5 ug(1,2,7) or PDV 30 ug(1,2,7) | T:169 | T:21 | NR | NR | NR | NR | NR |
C:189 | C:49 | ||||||||||
Repeated [48] | 2 | C: none | C: HBIG 100 IU(0,0.5) + RV 5ug(1,2,7) or PDV 30 ug(1,2,7) | T:318 | T:7 | NR | NR | NR | NR | NR | |
C:304 | C:22 | ||||||||||
Chen 2006 [49] | NR | 1 | T: HBIG 200 IU (7,8,9) | NR | T:16 | T: 4 | NR | NR | NR | NR | NR |
C:14 | C: 9 | ||||||||||
2 | C: none | T:34 | T: 1 | NR | NR | NR | NR | NR | |||
C:36 | C: 5 | ||||||||||
Yang 2006 [50] | NR | 1 | T: HBIG 200 IU (4–9) | NR | T:117 | T: 12 | T:7 | NR | NR | NR | NR |
C: None | C:90 | C: 48 | C: 0 | ||||||||
2 | T: HBIG 200 IU (7,8,9) | T:46 | T: 2 | T:10 | NR | NR | NR | NR | |||
C: None | C:32 | C:14 | C: 0 | ||||||||
Yu 2006 [51] | NR | 1 | T1: HBIG 200-400 IU (7–10) | NR | T1:8 | T1:3 | NR | NR | NR | NR | NR |
T2:7 | T2:5 | ||||||||||
C:8 | C: 8 | ||||||||||
2 | T2: HBIG 200 IU (7,8,9) | T1:18 | T1:0 | NR | NR | NR | NR | NR | |||
T2:22 | T2:0 | ||||||||||
C:20 | C:2 | ||||||||||
C: Diluent | |||||||||||
Ji 2007 [52] | NR | 1 | T: HBIG 200 IU (7,8,9) | T: HBIG 200 IU(0) + RV 5 ug(0,1,6) | T:30 | T:2 | NR | T: 1 | NR | NR | NR |
C:26 | C:10 | C: 6 | |||||||||
2 | C: None | C: HBIG 200 IU(0,0.5) + RV 5 ug(0,1,6) | T:83 | T:3 | NR | T: 1 | NR | NR | NR | ||
C:84 | C:5 | C: 3 | |||||||||
Liu 2007 [53] | NR | 1 | T: HBIG 200 IU (7,8,9) | T: HBIG 200 IU(0,0.5) + RV 10 ug(0,1,6) | T:12 | T: 1 | T: 4 | T: 0 | T:10 | NR | NR |
C:9 | C: 2 | C: 1 | C: 2 | C: 4 | |||||||
2 | C: None | C: HBIG 200 IU(0,0.5) + RV 10 ug(0,1,6) | T:31 | T: 1 | T: 12 | T: 0 | T:24 | NR | NR | ||
C:34 | C: 1 | C: 12 | C: 1 | C:25 | |||||||
Wang 2008 [54] | 20-33 | 1 | T:HBIG 200 IU(5–9) | T: HBIG 200 IU(0,0.5) + V | T:79 | T:8 | NR | T: 7 | NR | NR | NR |
C:60 | C: 19 | C: 14 | |||||||||
2 | C: None | C:V | T:80 | T: 2 | NR | T: 0 | NR | NR | NR | ||
C:60 | C:8 | C: 5 | |||||||||
Zhao 2008 [55] | 20-34 | 1 | T: HBIG 200 IU (7,8,9) | NR | T:37 | T: 6 | NR | NR | NR | NR | NR |
C:32 | C:12 | ||||||||||
2 | C: none | T:66 | T: 0 | NR | NR | NR | NR | NR | |||
C:69 | C:3 | ||||||||||
Liu 2009 [58] | NR | 1 | T: HBIG 200 IU (7,8,9) | NR | NR | NR | NR | NR | NR | NR | NR |
2 | C: none | T:100 | T: 1 | NR | NR | NR | NR | NR | |||
C:120 | C:4 | ||||||||||
Yuan 2009 [57] | 20-40 | 1 | T1: HBIG 200 IU (7,8,9) | T1: HBIG 200 IU(0,0.5) + RV 5 ug(0,1,6) | T1:4 | NR | NR | T1: 0 | T1:13 | NR | NR |
T2:9 | T2: 3 | T2: 7 | |||||||||
T2: None | T2: HBIG 200 IU(0,0.5) + RV 5 ug(0,1,6) | C:13 | C: 5 | C: 10 | |||||||
2 | C: None | C: RV 5 ug(0,1,6) | T1:23 | NR | NR | T1:1 | T1:23 | NR | NR | ||
T2:13 | T2:2 | T2:12 | |||||||||
C:13 | C: 1 | C: 7 | |||||||||
Li 2013 [58] | 24-35 | 1 | T: HBIG 200 IU (7,8,9) | T: HBIG 100 IU, 6 h + RV 10 ug, 0, 1,6 | T:38 | T:2 | T:34 | T:0 | T:36 | NR | NR |
C:34 | C:12 | C:15 | C:11 | C:15 | |||||||
2 | C: none | C: HBIG 100 IU, 6 h + RV 10 ug, 0, 1,6 | T:14 | T:0 | T:13 | T:0 | T:14 | NR | NR | ||
C:28 | C:3 | C:20 | C:1 | C:25 |
Reference | E 1)
| Infant’s Immune prophylaxis 2)(schedule/month ) | Sample size (n) | Newborn | 7-12month infant | >12 month child | |||
---|---|---|---|---|---|---|---|---|---|
HBsAg-pos | HBsAb-pos | HBsAg-pos | HBsAb-pos | HBsAg-pos | HBsAb-pos | ||||
1 | T: HBIG50 IU(0) + PDV5ug | T:36 | NR | NR | T:4 | T:32 | NR | NR | |
(0.5,1.5,2.5); C: PDV5ug (0.5,1.5,2.5) | C:38 | C: 9 | C:30 | ||||||
Sha 1985 [62] | 1 | T: HBIG 0.5 ml(0) + PDV 20ug (0,1,2,12); | T:19 | T:13 | T:18 | T:4 | T :10 | NR | NR |
C: PDV 20 ug(0,1,2,12) | C:10 | C:7 | C:0 | C:1 | C:5 | ||||
Wu 1986 [63] | 1 | T : HBIG 1 ml(0) + PDV 20ug (1,2,3) | T:13; | T:1; | NR | NR | NR | NR | NR |
C : PDV 20 ug(1,2,3) | C:6 | C:0 | |||||||
Farmer 1987 [64] | 1 | T: HBIG 0.25 ml (25 IU/kg)(0,1.5), | T:21 | NR | NR | T:3 | T:17 | NR | NR |
PDV5 ug(0,1.5, 6) C: PDV5 ug (0,1.5,6) | C:18 | C:4 | C:13 | ||||||
Theppisai 1987 [65] | 1 | T: HBIG 200 IU(0) + PDV 10 ug (0,1,6) | T:27 | NR | NR | T:2 | NR | NR | NR |
C: PDV 10 ug(0,1,6) | C:18 | C:2 | |||||||
1 | T: PDV3 ug(0,1,2,6) + HBIG(0) | T:64 | NR | NR | T:8 | NR | T:9 | T:47 | |
C: PDV3 ug(0,1,2,6) | C:64 | C:15 | C:15 | C:52 | |||||
Assateerawatt 1993 [68] | 1 | T:HBIG100IU(0) + RV20 ug (0,1,2,12) | T:30 | NR | NR | T:1 | T:25 | T:1 | T:24 |
C: RV20 ug(0,1,2,12) | C:30 | C:2 | C:22 | C:3 | C:21 | ||||
Li 1994 [69] | 1 | T : HBIG 200 IU(0) + PDV (0,1,6) | T1:20; C1:22 | T1:7; C1: 7; | T1:18;C1:3 | T1:1; C1:3 | T1:16; C1:19 | NR | NR |
C : PDV (1,2,3). | T2:20; C2:21 | T2:7; C2: 8; | T2:9; C2:2 | T2:7; C2:7 | T2:17; C2:11 | ||||
PDV including 10 ug, 20 ug and 30 ug | T3:22; C3:21 | T3:7; C3: 7 | T3:9; C3:2 | T3:1; C3:2 | T3:20; C3:20 | ||||
Zhao 1994 [70] | 1 | T : HBIG 60 IU(0) + V 10 ug (0,1,6) | T:40 | T:2 | T:35 | T:2 | T:36 | NR | NR |
C : V 10 ug(0,1,6) | C:26 | C:5 | C:9 | C:7 | C:15 | ||||
Kang 1995 [71] | 1 | T: HBIG 200 IU(0,1) + RV1 10 ug (0,1,6) | T:44 | NR | NR | NR | NR | T: 0 | T: 43 |
C: RV1 20 ug(0,1,6) | C:41 | C: 5 | C: 35 | ||||||
1 | T: HBIG 100 IU(0) + RV 10 ug (0,1,6,60) | T:64 | T:1 | NR | T: 0 | T: 58 | T:1 | T:39 | |
C: RV 10 ug(0,1,6,60) | C:63 | C:3 | C:3 | C: 54 | C:3 | C:35 | |||
Lin 2000 [75] | 1 | T : HBIG 50 IU(0) + RV 10 ug (0,1,6) | T:31 | T:4 | T: 26 | NR | NR | NR | NR |
C : RV 10 ug(0,1,6) | C:39 | C:2 | C: 36 | ||||||
Meng 2001 [76] | 1 | T : HBIG 50 IU(0) + RV 10 ug (0,1,6) | T:50 | NR | NR | NR | NR | T:4 | T:45 |
C : RV 10 ug(0,1,6) | C:52 | C:7 | C:43 | ||||||
1 | T: HBIG 100 IU(0,1) + RV 20 ug (1,2,7) | T:104; C:241 | T:20; C :76 | NR | T:21; C:81 | NR | T:26; C:96 | NR | |
2 | C: PDV 20 ug(0,1,6) | T:157; C:122 | T:19; C:25 | NR | T:22; C:26 | NR | T:28;C:35 | NR | |
1
3)
| T: HBIG0.5 ml(0) + PDV10 ug(0,1,2) | T:7; C:7 | NR | NR | T:1; C:1 | T:5;C:4 | NR | NR | |
2 | C: PDV10 ug(0,1,2) | T:17:C:14 | NR | NR | T:1; C:1 | T:13;C:13 | NR | NR | |
Xu 1995 [12] | 1 | T: HBIG 250 IU(0) + PDV 20 ug(0,1,6) | T:11; C:31 | NR | NR | T:1; C:10 | NR | T:1; C:10 | NR |
2 | C: PDV 20 ug(0,1,6) | T:17; C:29 | NR | NR | T:0; C:2 | NR | T:1; C:2 | NR |
Quality assessment
Meta-analysis results
Intrauterine and extrauterine prevention studies
Pregnancy infection status | Newborn infection status | Detective time | Number of included studies | Sample size | Meta-RR (95% CI) |
---|---|---|---|---|---|
Total (HBsAg+ and/or HBeAg+) | HBsAg+ | At birth | 23 | 4274 |
0.36(0.28, 0.45)
2)
|
7-12 month | 8 | 1036 |
0.34(0.22, 0.53)
2)
| ||
>12 month | 1 | 153 | 0.33(0.01, 7.95)2)
| ||
HBsAb+ | At birth | 7 | 1094 |
2.42(1.46, 4.01)
2)
| |
7-12 month | 6 | 757 | 1.12(1.00, 1.24)2)
| ||
>12 month | 1 | 153 | 1.07(0.86, 1.33)2)
| ||
Subgroup (HBsAg+ and HBeAg+) | HBsAg+ | At birth | 21 | 2159 |
0.40(0.32, 0.51)
2)
|
7-12 month | 8 | 812 |
0.37(0.23, 0.57)
3)
| ||
>12 month | 1 | 153 | 0.33(0.01, 7.95)2)
| ||
HBsAb+ | At birth | 7 | 909 |
3.05(2.19, 4.25)
2)
| |
7-12 month | 6 | 614 | 1.15(0.99, 1.34)2)
| ||
>12 month | 1 | 153 | 1.07(0.86, 1.33)2)
| ||
Subgroup (HBsAg+ and HBeAg-) | HBsAg+ | At birth | 15 | 1892 |
0.22(0.14, 0.35)
3)
|
7-12 month | 4 | 224 |
0.22(0.06, 0.84)
3)
| ||
HBsAb+ | At birth | 3 | 185 | 1.31(0.82, 2.10)3)
| |
7-12 month | 3 | 148 | 1.09(0.97, 1.22)3)
| ||
Subgroup (low+unclear bias) | HBsAg+ | At birth | 12 | 1945 |
0.35(0.22,0.54)
2)
|
7-12 month | 5 | 643 |
0.52(0.30,0.91)
3)
| ||
>12 month | 1 | 153 | 0.33(0.01,7.95)3)
| ||
HBsAb+ | At birth | 6 | 980 |
3.02(1.48,6.15)
2)
| |
7-12 month | 5 | 643 | 1.04(0.98,1.10)3)
| ||
>12 month | 1 | 153 | 1.07(0.86,1.33)3)
| ||
Subgroup (high risk bias) | HBsAg+ | At birth | 11 | 2329 |
0.37(0.29,0.47)
3)
|
7-12 month | 3 | 393 |
0.18(0.08,0.39)
3)
| ||
HBsAb+ | At birth | 1 | 114 |
1.60(1.26,2.03)
3)
| |
7-12 month | 1 | 114 |
1.49(1.23,1.81)
2)
|
Extrauterine prevention studies
Pregnancy infection status | Newborn infection status | Detective time | Number of included studies | Sample size | Meta-RR (95% CI) |
---|---|---|---|---|---|
Total (HBsAg+ and/or HBeAg+) | HBsAg+ | At birth | 7 | 1061 |
0.66(0.52,0.84)
3)
|
7-12 month | 12 | 1451 |
0.54(0.42,0.69)
3)
| ||
>12 month | 7 | 1214 |
0.54(0.42,0.69)
3)
| ||
HBsAb+ | At birth | 4 | 291 |
2.12(1.66,2.70)
3)
| |
7-12 month | 8 | 566 |
1.12(1.03,1.22)
3)
| ||
>12 month | 5 | 502 | 1.06(0.96,1.16)3)
| ||
Subgroup (HBsAg+ and HBeAg+) | HBsAg+ | At birth | 7 | 782 |
0.75(0.57,0.99)
3)
|
7-12 month | 12 | 1095 |
0.56(0.42,0.75)
3)
| ||
>12 month | 7 | 889 |
0.55(0.41,0.75)
3)
| ||
HBsAb+ | At birth | 4 | 291 |
3.25(1.35,7.83)
2)
| |
7-12 month | 9 | 443 |
1.14(1.05,1.24)
3)
| ||
>12 month | 5 | 502 | 1.06(0.96,1.16)3)
| ||
Subgroup (HBsAg+ and HBeAg-) | HBsAg+ | At birth | 1 | 279 | 0.59(0.34,1.02)3)
|
7-12 month | 3 | 356 | 0.64(0.39,1.06)3)
| ||
>12 month | 2 | 325 |
0.63(0.41,0.97)
3)
| ||
Subgroup (low + unclear bias) | HBsAg+ | At birth | 4 | 348 | 0.82(0.58,1.18)3)
|
7-12 month | 10 | 739 |
0.56(0.38,0.82)
3)
| ||
>12 month | 4 | 400 |
0.43(0.23,0.82)
3)
| ||
HBsAb+ | At birth | 3 | 221 |
4.21(2.70,6.57)
3)
| |
7-12 month | 8 | 566 |
1.12(1.03,1.22)
3)
| ||
>12 month | 4 | 400 | 1.05(0.93,1.17)3)
| ||
Subgroup (high risk bias) | HBsAg+ | At birth | 3 | 713 |
0.58(0.42,0.81)
3)
|
7-12 month | 2 | 712 |
0.53(0.39,0.72)
3)
| ||
>12 month | 3 | 814 |
0.56(0.43,0.73)
3)
| ||
HBsAb+ | At birth | 1 | 70 | 0.91(0.76,1.09) | |
7-12 month | - | - | - | ||
>12 month | 1 | 102 | 1.09(0.93,1.27) |